IMMUNIC, INC. Files 2023 Annual Report on Form 10-K

Ticker: IMUX · Form: 10-K · Filed: Feb 22, 2024 · CIK: 1280776

Immunic, INC. 10-K Filing Summary
FieldDetail
CompanyImmunic, INC. (IMUX)
Form Type10-K
Filed DateFeb 22, 2024
Risk Levelmedium
Pages15
Reading Time17 min
Key Dollar Amounts$0.0001, $410.9 million, $317.3 million, $431.4 million, $46.7 million
Sentimentneutral

Sentiment: neutral

Topics: IMMUNIC, IMUX, 10-K, Annual Report, SEC Filing

TL;DR

<b>IMMUNIC, INC. has filed its 2023 annual report (10-K) detailing its financial performance and business operations for the fiscal year ending December 31, 2023.</b>

AI Summary

IMMUNIC, INC. (IMUX) filed a Annual Report (10-K) with the SEC on February 22, 2024. IMMUNIC, INC. filed its 2023 Form 10-K on February 22, 2024. The company's fiscal year ends on December 31st. IMMUNIC, INC. is incorporated in Delaware. The company's principal executive offices are located in New York, NY. The filing covers the fiscal year ended December 31, 2023.

Why It Matters

For investors and stakeholders tracking IMMUNIC, INC., this filing contains several important signals. This 10-K filing provides a comprehensive overview of IMMUNIC, INC.'s financial health, operational activities, and strategic direction for the past fiscal year, which is crucial for investors to assess the company's performance and future prospects. As a public company, IMMUNIC, INC. is required to submit this report to the SEC, ensuring transparency and providing stakeholders with essential information for investment decisions.

Risk Assessment

Risk Level: medium — IMMUNIC, INC. shows moderate risk based on this filing. The company's financial performance and future prospects are subject to the inherent risks and uncertainties of drug development and commercialization, as detailed in the risk factors section of the 10-K.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand IMMUNIC, INC.'s current financial position and potential challenges.

Key Numbers

Key Players & Entities

FAQ

When did IMMUNIC, INC. file this 10-K?

IMMUNIC, INC. filed this Annual Report (10-K) with the SEC on February 22, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by IMMUNIC, INC. (IMUX).

Where can I read the original 10-K filing from IMMUNIC, INC.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by IMMUNIC, INC..

What are the key takeaways from IMMUNIC, INC.'s 10-K?

IMMUNIC, INC. filed this 10-K on February 22, 2024. Key takeaways: IMMUNIC, INC. filed its 2023 Form 10-K on February 22, 2024.. The company's fiscal year ends on December 31st.. IMMUNIC, INC. is incorporated in Delaware..

Is IMMUNIC, INC. a risky investment based on this filing?

Based on this 10-K, IMMUNIC, INC. presents a moderate-risk profile. The company's financial performance and future prospects are subject to the inherent risks and uncertainties of drug development and commercialization, as detailed in the risk factors section of the 10-K.

What should investors do after reading IMMUNIC, INC.'s 10-K?

Investors should review the detailed financial statements and risk factors in the 10-K to understand IMMUNIC, INC.'s current financial position and potential challenges. The overall sentiment from this filing is neutral.

How does IMMUNIC, INC. compare to its industry peers?

IMMUNIC, INC. operates in the pharmaceutical preparations industry, focusing on the development of novel immunomodulatory drugs.

Are there regulatory concerns for IMMUNIC, INC.?

As a publicly traded company, IMMUNIC, INC. is subject to the reporting requirements of the Securities and Exchange Commission (SEC), including the filing of annual reports on Form 10-K.

Industry Context

IMMUNIC, INC. operates in the pharmaceutical preparations industry, focusing on the development of novel immunomodulatory drugs.

Regulatory Implications

As a publicly traded company, IMMUNIC, INC. is subject to the reporting requirements of the Securities and Exchange Commission (SEC), including the filing of annual reports on Form 10-K.

What Investors Should Do

  1. Analyze the financial statements within the 10-K for revenue, expenses, and cash flow.
  2. Review the 'Risk Factors' section to understand potential challenges and uncertainties.
  3. Examine management's discussion and analysis (MD&A) for insights into business strategy and outlook.

Key Dates

Year-Over-Year Comparison

This is the initial filing analyzed, so no comparison to a previous filing is available.

Filing Stats: 4,362 words · 17 min read · ~15 pages · Grade level 15.1 · Accepted 2024-02-22 06:38:06

Key Financial Figures

Filing Documents

Business

Item 1. Business. 2

Risk Factors

Item 1A. Risk Factors. 19

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments. 56

Properties

Item 2. Properties. 57

Legal Proceedings

Item 3. Legal Proceedings. 57

Mine Safety Disclosures

Item 4. Mine Safety Disclosures. 57 PART II 58

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. 58

Selected Financial Data

Item 6. Selected Financial Data. 59

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. 60

Quantitative and Qualitative Disclosures About Market Risk

Item 7A. Quantitative and Qualitative Disclosures About Market Risk. 72

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data. 73

Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure. 73

Controls and Procedures

Item 9A. Controls and Procedures. 73

Other Information

Item 9B. Other Information. 74 PART III 75

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance. 75

Executive Compensation

Item 11. Executive Compensation. 75

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. 75

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence. 75

Principal Accountant Fees and Services

Item 14. Principal Accountant Fees and Services. 75 PART IV 76

Exhibits and Financial Statement Schedules

Item 15. Exhibits and Financial Statement Schedules. 76

Signatures

Signatures Special Note Regarding Forward-Looking Statements This Annual Report on Form 10-K ("Annual Report") contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These forward-looking statements are based on our management's current beliefs and assumptions and on information currently available to our management, and are contained principally in the sections entitled "Business," "Risk Factors," and "Management's Discussion and Analysis of Financial Condition and Results of Operations." Forward-looking statements include all statements that are not historical facts and can be identified by terms such as "anticipates," "believes," "best in class," "could," "seeks," "estimates," "expects," "first-in-class," "focused," "goal," "intends," "may," "objective," "opportunity," "pipeline," "plans," "potential," "predicts," "projects," "pursuing," "should," "target," "treatment option," "will," "would," "might," "can," "continue" or similar expressions and the negatives of those terms. These forward-looking statements include, among other things, statements about: the strategies, prospects, plans, expectations and objectives of management; our ability to maintain compliance with Nasdaq listing standards; strategies with respect to our development programs, including our ability to develop and commercialize our product candidates and the timing and expected data of clinical trials and preclinical studies; our estimates regarding revenues, expenses, capital requirements, projected cash requirements and needs for additional financing possible sources of funding for future operations; our ability to protect intellectual property rights and our intellectual property position; future economic conditions or performance; proposed products or product candidates; our ability to retain key pers

Business

Item 1. Business. Overview Immunic, Inc. ("Immunic," "we," "us," "our" or the "Company") is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. We are headquartered in New York City with our main operations in Grfelfing near Munich, Germany. We had 77 employees as of February 1, 2024. We are pursuing clinical development of orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase 3 clinical development for patients with multiple sclerosis ("MS") and which has shown therapeutic activity in Phase 2 clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis ("UC"); the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease ("IBD"), short bowel syndrome and irritable bowel syndrome with diarrhea; and the IMU-381 program, which is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. The following table summarizes the potential indications, clinical targets and clinical development status of our three product candidates: Our most advanced drug candidate, vidofludimus calcium (IMU-838), is being tested in several ongoing MS trials as part of its overall clinical program in order to support a potential approval for patients with MS in major markets. The Phase 3 ENSURE program of vidofludimus calcium in relapsing multiple sclerosis ("RMS"), comprising twin studies evaluating efficacy, safety, and tolerability of vidofludimus calcium versus placebo, and th

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing